Markets:

Overview

News

Currencies

International

Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

21.07 -0.48 (-2.20%)

Streaming Delayed Price Updated: 3:17 PM EDT, Apr 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

This IonQ Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

July 30, 2025

Via Benzinga

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday? ↗

July 30, 2025

Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controversies.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

July 30, 2025

Via Benzinga

Dow Futures Edge Up Ahead Of Fed Meeting, Big Tech Earnings: MSFT, META, F, HOOD, SRPT, SOFI Among Stocks To Watch ↗

July 30, 2025

While Dow Jones futures were up 0.03% at the time of writing, the S&P 500 futures rose 0.1%.

Via Stocktwits

Topics ETFs Economy Government

FDA Official Who Halted Sarepta’s Gene Therapy Resigns Amid Backlash Over Access To Duchenne Treatment ↗

July 30, 2025

Via Stocktwits

Why LendingClub Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket ↗

July 30, 2025

Via Benzinga

Why Did Sarepta Stock Jump 20% On Tuesday? Here’s What JPMorgan, Bernstein, Barclays Said About Elevidys ↗

July 29, 2025

JPMorgan upgraded Sarepta to ‘Neutral’ from ‘Underweight’ with a $24 price target.

Via Stocktwits

Topics Death

FDA Lifts Safety Hold On Sarepta's Muscular Dystrophy Gene Therapy—Wall Street Cheers ↗

July 29, 2025

Sarepta stock sees upgrades and price hikes as analysts reassess Elevidys prospects following a favorable FDA development.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

July 29, 2025

Via Benzinga

AMD Rises To 1-Year Highs, Crude Eyes $68: What's Moving Markets Tuesday? ↗

July 29, 2025

Risk appetite took a breather Tuesday, with major U.S. stock indices retreating modestly from record highs as investors braced for a pivotal stretch of earnings and macro events.

Via Benzinga

Crude Oil Gains Over 1%; UnitedHealth Earnings Miss Views ↗

July 29, 2025

Via Benzinga

Topics Earnings

Top movers analysis in the middle of the day on 2025-07-29: top gainers and losers in today's session. ↗

July 29, 2025

Curious to know what's happening on the US markets in the middle of the day on Tuesday? Join us as we explore the top gainers and losers in today's session.

Via Chartmill

Sarepta Stock Soars After FDA Says It Can Resume Drug Shipments ↗

July 29, 2025

Sarepta stock soared after the FDA said the biotech company can resume shipments of a controversial gene therapy drug.

Via Investor's Business Daily

Topics Workforce

Sanmina, Sarepta Therapeutics, Polaris, Celestica And Other Big Stocks Moving Higher On Tuesday ↗

July 29, 2025

Via Benzinga

There are notable gap-ups and gap-downs in today's session. ↗

July 29, 2025

In today's session, there are notable price gaps in the US markets on Tuesday. Take a closer look at the stocks that are gap up and gap down.

Via Chartmill

This Sarepta Therapeutics Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Tuesday ↗

July 29, 2025

Via Benzinga

Stay updated with the stocks that are on the move in today's pre-market session. ↗

July 29, 2025

Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

July 29, 2025

Via Benzinga

Why Celestica Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket ↗

July 29, 2025

Via Benzinga

Sarepta Therapeutics Surges Over 40% In Tuesday Pre-Market: What's Going On? ↗

July 29, 2025

Stock of Sarepta Therapeutics Inc. (NASDAQ: SRPT) surged 38.89% in Tuesday pre-market following the U.S. Food and Drug Administration's (FDA) recommendation to lift the voluntary hold on Elevidys,...

Via Benzinga

Nvidia, Sarepta, HPE, Citi, EQT: What Sparked Heavy After-Hours Trading In These 5 Stocks? ↗

July 28, 2025

Sarepta stock’s after-hours jump came as the FDA notified the company that it could lift the voluntary pause on the shipments.

Via Stocktwits

Topics Artificial Intelligence Credit Cards

BitMine Immersion, Sarepta Therapeutics, CEA Industries, Super Micro Computer And AMD: Why These 5 Stocks Are On Investors' Radars Today ↗

July 28, 2025

U.S. markets closed mixed on Monday, with the Dow Jones Industrial Average slipping 0.1% to 44,837.56.

Via Benzinga

Topics Stocks

Why Sarepta Therapeutics Stock Surged Nearly 48% In After-Hours Trading Today ↗

July 28, 2025

The FDA concluded that a recent patient death in Brazil was unrelated to Sarepta’s Elevidys treatment, allowing the company to resume U.S. shipments for boys who can still walk.

Via Stocktwits

Sarepta Therapeutics Stock Soars After FDA Removes Hold On Elevidys For Some Patients ↗

July 28, 2025

Sarepta Therapeutics shares are halted in extended trading Monday after the U.S. Food and Drug Administration (FDA) recommended the removal of a voluntary hold for Elevidys.

Via Benzinga

FDA Probes Death Of 8-Year-Old Who Received Sarepta's Elevidys ↗

July 28, 2025

FDA probes Elevidys after an 8-year-old's death in Brazil; Sarepta and Roche say the death was unrelated to gene therapy treatment.

Via Benzinga

Retail Bulls Stick With Sarepta After 8-Year-Old Patient’s Death Deemed Unrelated To DMD Gene Therapy ↗

July 28, 2025

The update comes as Sarepta faces mounting regulatory scrutiny, including an ongoing FDA investigation and a recommendation from European regulators to reject approval of Elevidys.

Via Stocktwits

Topics Death

Sarepta Gets Thumbs Down From Regulators Regarding Elevidys Gene Therapy ↗

July 25, 2025

Sarepta and Roche face a regulatory setback as the EMA's CHMP issues a negative opinion on Elevidys for Duchenne muscular dystrophy patients.

Via Benzinga

Sarepta Stock Slumps After EU Regulator Recommends Refusing Approval To Its Contentious Gene Therapy: Retail Expects Stock Bounceback ↗

July 25, 2025

Roche announced on Friday that it plans to continue working with the EMA to explore a potential path forward.

Via Stocktwits

Topics Death

Sarepta Therapeutics' Brutal Week Continues With Bad News Out Of Europe ↗

July 25, 2025

Shares are down another double-digit percentage after bad news continued piling on for gene therapy Elevidys.

Via Investor's Business Daily

Topics Death

Intel, Absci, AST SpaceMobile And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

July 25, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

Headline News about Sarepta Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today